Testosterone Sold as SARMs: What the Paradigm Peptides Case Reveals About Unverified Sourcing

The Paradigm Peptides case illustrates why a product label, a purity percentage, and verified chemical identity answer different questions. This article combines the case timeline with a practical framework for evaluating batch documentation.

Case timeline and court orders

According to the Department of Justice sentencing announcement, Paradigm sold products to approximately 54,000 customers between 2019 and 2024. FDA warnings followed in 2020 and 2022. The company imported inventory, sold it without testing, and made false domestic-manufacturing and FDA-approval claims. Testing found testosterone in products marketed as SARMs.

On July 30, 2026, DOJ announced that Michael Kawa received 70 months in prison and Jodi Stechkober received 16 months, each followed by one year of supervised release. The court also ordered $78,317.52 in restitution and a $5 million money judgment. Read the underlying announcement for the charges, attribution, and court's findings.

Why purity cannot establish identity

A high chromatographic peak-area percentage describes the measured separation under a particular method. It does not, by itself, establish that the dominant peak is the substance on the label. A highly purified wrong compound is still the wrong material.

Identity assessment needs suitable analytical methods and reference information. Mass spectrometry can support a molecular assignment, but a matching mass alone may not distinguish sequence isomers or every impurity. The method, sample preparation, and acceptance criteria matter as much as the instrument name. Read how to interpret a COA for the distinction between purity, identity, and quantity.

A traceable batch-review process

Match the vial identifier to the actual laboratory report. Record the report number, test date, sample description, methods, and results. If authenticity is uncertain, verify the report directly with the named laboratory using independently obtained contact details.

Then ask a separate question: does that report describe the material received? A genuine report can concern a different sample. Receiving records, lot identifiers, and documented sampling help connect the result to the shipment. Preserve those records when a lot changes so an experimental difference can be investigated.

What documentation cannot prove

A warehouse address establishes a fulfillment location, not where synthesis, purification, or testing occurred. Likewise, a laboratory logo does not establish the scope of its methods or prove that a particular batch passed them.

Chemical identity, quantity, endotoxin, and microbial testing address different attributes. Select the necessary tests and acceptance criteria for the research model. An independent report can add a check on supplier claims; it does not remove the need to inspect methods and sample provenance. In-house testing can also be informative when its controls and records are available.

For a complete sourcing checklist, see how to source research peptides.

Frequently asked questions

Can a purity number rule out substitution?

No. Purity and identity are different measurements. Inspect the actual identity evidence and its limitations.

Does a domestic shipping address prove domestic manufacturing?

No. Request documentation for the individual manufacturing and fulfillment stages.

Does a verified COA establish clinical safety?

No. Analytical results concern the tested sample and attributes. They do not establish clinical safety or efficacy.